Isomorphic, which formed as an Alphabet company in 2021, has a massive cash horde, but it’s tight-lipped on what drugs it ...

The proceeds will be used to accelerate Isomorphic Labs’ pipeline of therapeutic programmes and further develop its IsoDDE AI drug design engine.

Fathom Therapeutics, formerly Atommap Corp., a company that uses quantum chemistry and AI to design novel drug molecules by predicting their behavior inside living cells, today announced an ...

If any proof was needed that big money is still available for AI drug development, look no further than the ten-figure series B hauled in by Isomorphic Labs. The London-based AI drug discovery firm ...

May 12 (Reuters) - Isomorphic Labs, an artificial intelligence-driven drug discovery company, said on Wednesday it has raised ...

Ligand-based drug design combines AI and QSAR modeling to prioritize drug candidates, minimizing preclinical failures and ...

Massive funding round: Isomorphic Labs secured $2.1B from investors including Thrive Capital, Alphabet, and the UK Sovereign AI Fund to expand AI drug discovery. Tech to trials: Funds will accelerate ...

Isomorphic Labs secures $2.1 billion in funding to accelerate its AI-powered drug discovery engine and scale pharmaceutical ...

In the search for new drugs, artificial intelligence in the form of diffusion models is being used in drug design. What ...

Drug discovery still too often relies on expensive trial and error. Researchers from ICTER show there is another way—building ...

Isomorphic Labs will use the funding to power its world-leading AI drug design engine, scale its business globally and progress its drug candidate pipeline.

Despite significant progress in medicinal chemistry and life sciences research, drug discovery and development remain slow and expensive, taking on average approximately 15 years and US$2 billion to ...